Expanded Access Program With Nivolumab to Treat Melanoma

Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)

Status

NO_LONGER_AVAILABLE

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT02142218

Acronym

Checkmate 168

Enrollment

Unknown

Registered

2014-05-20

Start date

2014-06-30

Completion date

2018-05-31

Last updated

2016-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III (Unresectable) or Stage IV Advanced Melanoma

Brief summary

The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.

Interventions

DRUGNivolumab

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * ECOG Performance Status of 0-1 * Histologically confirmed malignant melanoma * Progressed on or after treatment with an anti-CTLA4

Exclusion criteria

* Active brain metastases * Life Expectancy \<6 weeks * Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy * Subjects with autoimmune disease

Countries

Argentina, Brazil, Canada, Colombia, Peru, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026